Lily Pham
Neurology · Baltimore, MDNPI 1407218282
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $1,663 of the $2,021 with a category attached, or 82.2%. Servier Pharmaceuticals LLC accounts for 84.0% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2024 at $1,771 and has fallen 91.6% since, to $149 in 2025.
Across 15 payments — averaging $134.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Servier Pharmaceuticals LLC$2K
- AstraZeneca$117
- Takeda Pharmaceuticals U.S.A., Inc.$49
- Tersera Therapeutics LLC$36
- Merck$33
- Daiichi Sankyo Inc.$29
- plus $60 from 3 others
Across 1 payment — averaging $630.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Jazz Pharmaceuticals Inc.$630
What the payments were for
- Consulting fees$1,66382%
- Food & beverage$35918%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Servier Pharmaceuticals LLC | 2 | $1,698 |
| AstraZeneca | 4 | $117 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $49 |
| Tersera Therapeutics LLC | 1 | $36 |
| Merck | 2 | $33 |
| Daiichi Sankyo Inc. | 1 | $29 |
| Exelixis Inc. | 1 | $25 |
| Caris MPI, Inc. | 1 | $20 |
| Monteris Medical Corporation | 1 | $15 |
How this compares
$2,021 in reported general payments places this provider in the 55th percentile of 442 neurology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ondansetron Hcl | 13 | $976 |
| Levetiracetam | 43 | $801 |
| Dexamethasone | 15 | $273 |
Paid to pharmacies, not to this prescriber.
Other neurology in Baltimore
- Michael PolydefkisBaltimore$371K
- Shiv SaidhaBaltimore$298K
- Santiago Mazuera MesiaBaltimore$258K
- Thomas CrawfordBaltimore$215K
- Scott NewsomeBaltimore$203K
- Perry ForemanBaltimore$194K
- Samuel MillerBaltimore$179K
- Ted DawsonBaltimore$170K
- Charlene GamaldoBaltimore$131K
- Kathryn WagnerBaltimore$120K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.